Jan 31, 2018

Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals. 

Go to article (external link)